Back

Effect on Oxidized Phospholipids of Lepodisiran, an Extended Duration siRNA Targeting Lipoprotein(a)

31 August 2026 (09:30 - 09:45)
Organised by: Logo
Congress Presentation Part of: Beyond statins: the next wave of lipid-lowering therapies Drug therapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Steven E Nissen

Cleveland Clinic Hospital, Cleveland (United States of America)

5 More presentations in this session

Presentation thumbnail
Head-to-head comparison of inclisiran vs bempedoic acid for LDL C lowering in patients with high and very high cardiovascular risk: Results from the phase 4 VICTORION-CHALLENGE trial
Professor I. Hilgendorf (Berlin, DE)
Presentation thumbnail
Oral HRS-5346, a novel small molecule lipoprotein(a) inhibitor, in adults at high cardiovascular risk with elevated lipoprotein(a): a phase 2, randomized, double-blind study
Doctor D. Zhu (Beijing, CN)
Presentation thumbnail
Protocol-based early intensive lipid management in patients with acute coronary syndrome (BRIDGE): A multicenter prospective cluster-randomized controlled trial
Doctor K. Oyama (Sendai, JP)
Presentation thumbnail
A phase 3 clinical trial to evaluate the efficacy and safety of vsa003 injection in chinese adolescents and adults with homozygous familial hypercholesterolaemia (hofh)
Doctor Z. Tian (Beijing, CN)
Presentation thumbnail
Effects of Evolocumab on Fatal Outcomes in Patients Without a Prior Myocardial Infarction or Stroke : Pre-specified Analysis of the VESALIUS-CV Trial
Doctor R. Giugliano (Boston, US)

Access the full session

Session thumbnail
Beyond statins: the next wave of lipid-lowering therapies

The Event

Event poster

ESC Congress 2026

31 August 2026 09:30 CET
You may be interested in
thumbnail
Webinar
Lipoprotein(a): current role and future perspectives in cardiovascular medicine
31 October 2025
thumbnail
Congress Presentation
Safety and efficacy of zodasiran, a hepatic sirna targeting angptl3, in mixed hyperlipidemia patients: 2 year open label extension (OLE) results from ARCHES-2
31 August 2025
thumbnail
Congress Presentation
The association between non-Lp(a)-ApoB / Lp(a) ratio and plaque vulnerability according to lipid oxidation status
29 August 2026
thumbnail
Congress Presentation
Carotid plaques stabilization and regression with evolocumab
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources